Axsome Therapeutics Inc., a biopharmaceutical company developing new therapies for central nervous system disorders, has acquired Sunosi (solriamfetol) from Jazz Pharmaceuticals.

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor designed to improve wakefulness in adult patients with excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea. It was approved by the U.S. FDA in 2019 and EMA in 2020. The drug is the first and only DNRI approved to treat adults living with EDS due to narcolepsy or OSA. The purchase will enhance Axsome’s development into a commercial entity and strengthen its neuroscience offerings.

“This acquisition immediately transforms Axsome into a global commercial entity, upon closing, and accelerates our growth as a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions,” said Herriot Tabuteau, MD, CEO of Axsome. “Sunosi has demonstrated clinically meaningful efficacy, possesses a unique mechanism of action, and has generated positive patient and physician feedback. We are excited by its significant growth potential and excellent strategic fit with the Axsome portfolio.”

DLA Piper represented Axsome as part of its acquisition of Sunosi.